
Roche Holding (SWX:ROP) is back in focus after regulators in Europe moved a step closer to clearing Gazyva/Gazyvaro as an add on therapy for hard to treat systemic lupus erythematosus.
Over the past year, momentum around Roche Holding has picked up, with a year to date share price return of 25.75% and a 1 year total shareholder return of 46.88% that lines up with a steady stream of Gazyva and diagnostics milestones.
Scan for other healthcare compounders riding similar clinical and diagnostic catalysts by checking the hand picked 125 healthcare AI stocks alongside Roche Holding’s recent activity.
Roche Holding now trades above the average analyst target, yet screens on some models at a more than 50% discount to intrinsic value. Is the recent clinical momentum enough to challenge that market caution?
Roche Holding last closed at CHF409.30, above the analyst consensus Narrative fair value of CHF383.96. This estimate uses a 3.95% discount rate and ties directly to detailed revenue and earnings forecasts from the Street.
Late stage pipeline breadth, including 10 new molecular entities moving into Phase III and the potential launch of up to 19 medicines by the end of the decade, gives Roche multiple shots on goal that can feed new revenue lines and help offset loss of exclusivity impacts on earnings.
See why 20 investors see Roche Holding as 7% overvalued.
Result: Fair Value of CHF383.96 (OVERVALUED)
Still, Roche Holding faces real pressure if China pricing reforms spread further or if biosimilars erode key franchises more quickly than new launches can ramp up.
Find out about the key risks to this Roche Holding narrative.
Where the analyst narrative tags Roche Holding as 6.6% overvalued on a fair value of CHF383.96, the SWS DCF model lands somewhere very different. On that framework, the shares at CHF409.30 trade about 53% below an estimated future cash flow value of CHF876.78. Which version of fair value do you think your thesis leans on?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Roche Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 212 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Mixed signals on Roche Holding’s value can make any investor pause, so move quickly from headline takes to your own judgment by weighing its 3 key rewards and 1 important warning sign.
If you want a fuller watchlist, let the Simply Wall Street Screener surface fresh ideas so you are not relying on Roche Holding alone.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com